3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
pembrolizumab
64
Carboplatin
63
Paclitaxel
54
Magnetic Resonance Spectroscopy
45
Specimen Handling
43
Cisplatin
43
Gemcitabine
35
Bevacizumab
31
Docetaxel
30
Doxorubicin
29
Leucovorin
28
Fluorouracil
27
Dexamethasone
27
Cyclophosphamide
26
Pemetrexed
25
Radiation
23
Oxaliplatin
23
Radiotherapy
22
Etoposide
22
durvalumab
21
Nivolumab
21
Letrozole
21
Vincristine
20
Rituximab
20
Irinotecan
20
Taxes
19
Prednisone
19
Capecitabine
19
Lenalidomide
18
130-nm albumin-bound paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
BID protein, human
×
30 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled